Monday, July 22, 2019

Targeting old bottleneck reveals new anticancer drug strategy

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists at Winship Cancer Institute of Emory University have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/targeting-old-bottleneck-reveals-new-anticancer-drug-strategy